HC Wainwright Has Bearish Estimate for ARCT Q2 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities research analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Arcturus Therapeutics in a report issued on Wednesday, May 13th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn ($0.99) per share for the quarter, down from their prior forecast of ($0.82). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Arcturus Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.78) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($2.99) EPS, FY2029 earnings at ($3.95) EPS and FY2030 earnings at ($4.42) EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.08. The business had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%.

ARCT has been the topic of several other reports. Citigroup dropped their target price on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Piper Sandler lowered their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Weiss Ratings upgraded Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. Roth Mkm initiated coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price objective on the stock. Finally, B. Riley Financial started coverage on shares of Arcturus Therapeutics in a research report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.44.

Arcturus Therapeutics Trading Down 5.2%

Shares of ARCT opened at $7.83 on Friday. The firm has a market cap of $222.53 million, a PE ratio of -2.79 and a beta of 2.43. Arcturus Therapeutics has a 12 month low of $5.85 and a 12 month high of $24.17. The stock has a fifty day moving average price of $7.91 and a 200-day moving average price of $7.57.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its position in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 738 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth about $64,000. Intech Investment Management LLC acquired a new stake in shares of Arcturus Therapeutics during the fourth quarter worth about $70,000. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of Arcturus Therapeutics by 65.1% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 4,737 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.